Skip to main content
Novoheart Holdings Inc. logo

Novoheart Holdings Inc. — Investor Relations & Filings

Ticker · NVH ISIN · CA67011V1076 LEI · 254900J0TE0F61S1DB96 TSXV Professional, scientific and technical activities
Open in API
Filings indexed 197 across all filing types
Latest filing 2020-11-28 Regulatory Filings
Country CA Canada
Listing TSXV NVH

About Novoheart Holdings Inc.

https://www.novoheart.com/

Novoheart Holdings Inc. is a stem cell biotechnology holding company specializing in the engineering of bioartificial human heart surrogates and next-generation cardiac tissue prototypes. The company utilizes state-of-the-art bioengineering approaches and human stem cell-derived cardiomyocytes to create its core product, the mini-Heart Platform. This platform consists of advanced engineered-tissue formats designed for comprehensive assessment of cardiac functional outputs. Novoheart provides bioengineered human cardiac tissue models and related services for drug discovery, disease modeling, and pharmaceutical screening. The platform supports over 12 disease models, including those for Heart Failure with preserved Ejection Fraction (HFpEF), Arrhythmias, and COVID-19 cardiotoxicity. By offering human-relevant models, Novoheart aims to accelerate research, improve efficacy, and reduce costs by eliminating reliance on animal testing.

Recent filings

Filing Released Lang Actions
Material change report - English.pdf
Regulatory Filings Classification · 95% confidence The document is a FORM 51-102F3 Material Change Report filed by Novoheart Holdings Inc. It details a material change event, specifically the completion of an acquisition and subsequent delisting from the TSX Venture Exchange. The document includes a summary and full description of the material change, references to regulatory approvals, and forward-looking statements. It is not a full financial report, audit, or earnings release, but rather a regulatory filing reporting a significant corporate event. The document length (6865 characters) and content indicate it is a formal regulatory announcement of a material change, consistent with a Regulatory Filing (RNS) rather than a report or announcement of a report publication. Therefore, the appropriate classification is Regulatory Filings (RNS).
2020-11-28 English
Notice.pdf
Delisting Announcement Classification · 95% confidence The document is titled 'NOTICE OF CHANGE IN CORPORATE STRUCTURE PURSUANT TO SECTION 4.9 OF NATIONAL INSTRUMENT 51-102' and describes a transaction where Novoheart Holdings Inc. was acquired and became a wholly-owned subsidiary of the Purchaser. It details the transaction date, approval by shareholders and court, and the delisting of Novoheart from the TSX Venture Exchange. The document also states that Novoheart has applied to cease being a reporting issuer. The content focuses on the corporate restructuring and delisting event rather than financial results or management commentary. The document length is 3720 characters, which is relatively short and reads like an official announcement. Given the description of the delisting and cessation of reporting status, the document fits best as a Delisting Announcement (DLST).
2020-11-27 English
News release - English.pdf
Regulatory Filings
2020-11-18 English
News release - English.pdf
M&A Activity Classification · 95% confidence The document is a press release announcing the final court approval of a going-private transaction involving Novoheart Holdings Inc. It details the acquisition terms, mentions the plan of arrangement under the Business Corporations Act, and references prior management information circulars. There is no detailed financial data, quarterly or annual financial statements, or audit information. The document is an announcement of a corporate transaction (going-private acquisition) rather than a full report or filing. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. The content aligns with a Merger & Acquisition related announcement, specifically about a going-private transaction and acquisition approval. Therefore, the most appropriate classification is M&A Activity (TAR). The document length (6406 characters) supports it being a full announcement rather than a brief notice or report publication announcement.
2020-11-16 English
News release - English.pdf
Delisting Announcement Classification · 95% confidence The document is a press release announcing that Novoheart Holdings Inc. has received securityholder approval for a going-private transaction involving a plan of arrangement. It details the approval percentages from the special meeting, the delisting approval from the TSX Venture Exchange, and the terms of the transaction. It also mentions the upcoming court hearing for final approval and references a management information circular dated October 9, 2020, available on SEDAR. The document does not contain financial statements or detailed financial analysis but is an announcement of a corporate transaction and related shareholder vote results. It is not a full annual or interim report, audit report, or earnings release. It is also not a proxy solicitation or voting results announcement alone, but rather a corporate transaction announcement including voting results and delisting approval. The best fitting category is Delisting Announcement (DLST) because the document prominently announces the approval of the delisting of the company's shares from the TSXV as part of the going-private transaction. Confidence is high given the clear focus on the going-private transaction and delisting approval.
2020-11-11 English
Certificate re dissemination to shareholders.pdf
Proxy Solicitation & Information Statement Classification · 85% confidence The document is a letter from TSX Trust Company confirming the mailing of proxy-related materials for Novoheart Holdings Inc. It lists various proxy materials such as Proxy forms, Voting Instruction Form, Notice of Meeting Combined with Information Circular, Letter of Transmittal, and related documents sent to shareholders and other parties. The document is short (1358 characters) and serves as a confirmation of distribution of proxy materials rather than the proxy materials themselves. This fits the description of Proxy Solicitation & Information Statement (PSI) materials being sent out, but since this document is a confirmation of mailing rather than the proxy statement itself, it is best classified as a Regulatory Filing (RNS) as a general regulatory announcement. However, given the specific nature of the content about proxy materials, the best fitting category is Proxy Solicitation & Information Statement (PSI). The document is not the proxy statement itself but is closely related to proxy solicitation. Given the short length and nature, the confidence is high but not absolute since it is a confirmation letter rather than the proxy statement itself.
2020-10-20 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.